Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

US FDA’s Regulatory Affairs Office Building Case For More User Fee Funding

Executive Summary

ORA represented only a small fraction of the user fee programs’ costs in recent years, but wants to show its importance to the review process.

You may also be interested in...



Bending PDUFA’s Cost Curve: PhRMA Looking For Sustainable Program Growth

Industry feels that sufficient program management tools are in place, but a PDUFA VII negotiator says they need more time to mature.

US FDA’s In-Person Foreign Inspections Remain On House Appropriators’ Minds

The House Appropriations Committee also does not want the agency to become too dependent on alternative inspection tools.

Domestic In-Person Inspection Work Could Be Back To Normal This Summer, Woodcock Says

Foreign facility visits may take longer to reach usual levels because of the ongoing coronavirus outbreaks in other countries.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS144649

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel